Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Filamon LTD
Trogenix ltd
Eli Lilly and Company
Neonc Technologies, Inc.
M.D. Anderson Cancer Center
Lantern Pharma Inc.
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Essen Biotech
Essen Biotech
Grupo Español de Investigación en Neurooncología
Genenta Science
Sapience Therapeutics
Washington University School of Medicine
Cantex Pharmaceuticals
Institute of Cancer Research, United Kingdom
Tango Therapeutics, Inc.
Inovio Pharmaceuticals
Institute of Cancer Research, United Kingdom
InSightec
InSightec
Case Comprehensive Cancer Center
AHS Cancer Control Alberta
M.D. Anderson Cancer Center
Mianyang Central Hospital
University of Miami
Universitair Ziekenhuis Brussel
Turning Point Therapeutics, Inc.
GlaxoSmithKline
Incyte Corporation
NeuGATE Theranostics
University of Arizona
Jonsson Comprehensive Cancer Center
Duke University
Aveta Biomics, Inc.
M.D. Anderson Cancer Center
LigaChem Biosciences, Inc.
Shenzhen Geno-Immune Medical Institute
Hemerion Therapeutics
Rznomics, Inc.
Cedars-Sinai Medical Center
Kintara Therapeutics, Inc.
Nerviano Medical Sciences
Incyte Corporation
University Hospital, Essen
Alaunos Therapeutics
Université de Sherbrooke